Cargando…

PB1995: THE USEFULNESS OF NEUTROPHIL NEW PARAMETERS ASSESSMENTS AS AN ELEMENT TO DISTINGUISH PATIENTS WITH GENETIC CHANGES IN MYELODYSPLASTIC SYNDROME - A PRELIMINARY STUDY

Detalles Bibliográficos
Autores principales:	Kulik, Katarzyna, Gawronski, Krzysztof, Rutkowska, Elżbieta, Kwiecień, Iwona, Raniszewska, Agata, Dudzik, Alicja, Zakrzewska, Agata, Sawicki, Waldemar, Rzepecki, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430423/ http://dx.doi.org/10.1097/01.HS9.0000974796.85248.30

Ejemplares similares

PB1991: NEW MONOCYTE HEMATOLOGICAL PARAMETERS AS AN IMPORTANT INDICATOR OF MDS PATIENTS WITH POSITIVE OGATA SCORE - A PRELIMINARY STUDY
por: Dudzik, Alicja, et al.
Publicado: (2023)

Usefulness of New Neutrophil-Related Hematologic Parameters in Patients with Myelodysplastic Syndrome
por: Kwiecień, Iwona, et al.
Publicado: (2023)

PB1994: COMPARISON OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITH HIGH AND LOW OGATA SCORE VALUES ON CYTOMETRY IN RELATION TO THE PRESENCE OF CYTOGENETIC ABNORMALITIES - A PRELIMINARY STUDY
por: Gawronski, Krzysztof, et al.
Publicado: (2023)

Neutrophil Maturation, Reactivity and Granularity Research Parameters to Characterize and Differentiate Convalescent Patients from Active SARS-CoV-2 Infection
por: Kwiecień, Iwona, et al.
Publicado: (2021)

Lung Cancer Stem Cells—Origin, Diagnostic Techniques and Perspective for Therapies
por: Raniszewska, Agata, et al.
Publicado: (2021)

Modulation of the immune response by heterogeneous monocytes and dendritic cells in lung cancer
por: Kwiecień, Iwona, et al.
Publicado: (2021)

Blood Monocyte Subsets with Activation Markers in Relation with Macrophages in Non-Small Cell Lung Cancer
por: Kwiecień, Iwona, et al.
Publicado: (2020)

Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry
por: Kwiecień, Iwona, et al.
Publicado: (2021)

T Lymphocyte Maturation Profile in the EBUS-TBNA Lymph Node Depending on the DLCO Parameter in Patients with Pulmonary Sarcoidosis
por: Rutkowska, Elżbieta, et al.
Publicado: (2021)

Effector Memory T Cells and CD45RO+ Regulatory T Cells in Metastatic vs. Non-Metastatic Lymph Nodes in Lung Cancer Patients
por: Kwiecień, Iwona, et al.
Publicado: (2022)

Flow Cytometric Analysis of Macrophages and Cytokines Profile in the Bronchoalveolar Lavage Fluid in Patients with Lung Cancer
por: Kwiecień, Iwona, et al.
Publicado: (2023)

Immunomodulatory Molecules On Lung Cancer Stem Cells From Lymph Nodes Aspirates
por: Raniszewska, Agata, et al.
Publicado: (2020)

Cytokines and Leukocytes Subpopulations Profile in SARS-CoV-2 Patients Depending on the CT Score Severity
por: Rutkowska, Elżbieta, et al.
Publicado: (2021)

PB1997: TRISOMY 18 IN MYELODYSPLASTIC SYNDROMES
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2023)

Usefulness of the New Hematological Parameter: Reactive Lymphocytes RE-LYMP with Flow Cytometry Markers of Inflammation in COVID-19
por: Rutkowska, Elżbieta, et al.
Publicado: (2021)

PB2015: DIAGNOSIS, CLASSIFICATION AND STRATIFICATION OF MYELODYSPLASTIC SYNDROMES IN ALGERIA
por: Moussa, Yamina Bouchakour, et al.
Publicado: (2023)

PB2020: OUTCOMES OF PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES
por: Amor, Imen Ben, et al.
Publicado: (2023)

PB2025: CULTURAL DATA TO NEW CLASSIFICATION OF MYELODYSPLASTIC NEOPLASIA
por: Saralidze, Tamar, et al.
Publicado: (2023)

PB1916: SOMATIC MUTATIONS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME IN RUSSIAN PATIENTS
por: Kohno, A., et al.
Publicado: (2022)

PB1996: CYTOGENETIC FEATURES OF 164 MOROCCAN PATIENTS WITH MYELODYSPLASTIC SYNDROME
por: Aghoutane, Yossra, et al.
Publicado: (2023)

PB1992: PROTEOMIC ANALYSIS REVEALS AUTOPHAGY INHIBITION IN MYELODYSPLASTIC SYNDROMES
por: Tsekoura, Georgia, et al.
Publicado: (2023)

PB2026: ROLE OF MOLECULAR PROFILING IN MYELODYSPLASTIC SYNDROME IN REAL-WORLD - A NEW APPROACH IN MYELODYSPLASTIC SYNDROME’S RISK STRATIFICATION?
por: Silva, Duarte Pacheco, et al.
Publicado: (2023)

PB1914: CYTOGENETIC FINDINGS IN 18 CHILDREN WITH MYELODYSPLASTIC SYNDROMES BY KARYOTYPIC AND FISH ANALYSIS
por: Manola, K., et al.
Publicado: (2022)

PB2029: ACQUIRED ALPHA THALASSEMIA IN ASSOCIATION WITH MYELODYSPLASTIC SYNDROME- A CASE REPORT
por: Balasubramanian, Priyavadhana, et al.
Publicado: (2023)

PB2011: TRANSFUSION BURDEN IS AN IMPORTANT PROGNOSTIC FACTOR IN LOWER-RISK MYELODYSPLASTIC SYNDROME
por: Lee, Jungmin, et al.
Publicado: (2023)

PB2013: THE FREQUENCY, EVOLUTION AND SIGNIFICANCE OF GENE MUTATION IN MYELODYSPLASTIC SYNDROMES WITH NORMAL KARYOTYPE
por: Xu, Feng, et al.
Publicado: (2023)

Intermediate Monocytes with PD-L1 and CD62L Expression as a Possible Player in Active SARS-CoV-2 Infection
por: Rutkowska, Elżbieta, et al.
Publicado: (2022)

Analysis of Argyrophilic Nucleolar Organizer Regions (AgNORs) in Acute Leukemia in Adults
por: Gajewska, Małgorzata, et al.
Publicado: (2022)

AgNOR patterns and configurations in adult acute leukemia patients
por: Gajewska, Małgorzata, et al.
Publicado: (2023)

PB2022: ELTROMBOPAG IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

PB2001: PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES- A SWEDISH RETROSPECTIVE REAL-WORLD STUDY
por: Schain, Frida, et al.
Publicado: (2023)

Role of fibrocytes and endothelial progenitor cells among low-differentiated CD34+ cells in the progression of lung sarcoidosis
por: Elżbieta, Rutkowska, et al.
Publicado: (2020)

PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)
por: Cerchione, C., et al.
Publicado: (2022)

PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES
por: Zeidan, A., et al.
Publicado: (2022)

PB2672: EXPLORING UNMET NEEDS OF PATIENTS WITH MYELODYSPLASTIC NEOPLASMS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY
por: Crisà, Elena, et al.
Publicado: (2023)

PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY
por: Corry, Sorcha, et al.
Publicado: (2023)

PB2027: EFFICACY OF THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROME WITH UNFAVORABLE IMMUNOPHENOTYPIC AND CYTOGENETIC PROGNOSIS.
por: Trubkina, Hanna, et al.
Publicado: (2023)

PB1995: SAFETY OF SUBCUTANEOUS DARATUMUMAB IN MULTIPLE MYELOMA: A RETROSPECTIVE MULTI-CENTER REAL LIFE EXPERIENCE
por: De Novellis, D., et al.
Publicado: (2022)

PB1924: ARE WE TAKING ADVANTAGE OF THERAPEUTIC OPTIONS IN MYELODYSPLASTIC SYNDROME?-REAL WORLD DATA FROM HUNGARY
por: Miltényi, Z., et al.
Publicado: (2022)

PB2206: FULL SPECTRAL FLOW CYTOMETRY ANALYSIS OF THE BONE MARROW IMMUNE MICROENVIRONMENT IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
por: chen, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oihad6p6q3f5m5ma09fi48q0a6